From a historical view, Biopharmaceuticals are no new business. Antibiotics and vaccines have been well known for more than 60 years. But with the marketing authorisation of the first pharmaceutical product, produced by gene technology in the 80s, a new era of biopharmaceutical and biotechnological development and manufacturing started.

In 2007, 20% of all new released pharmaceuticals were Biopharmaceuticals. In defiance of all throw-backs in the last years, pharmaceutical products based on biotechnology succeeded in gaining substantial market shares - and this trend can be expected to continue. Furthermore, after the end of the protection of patents, biotechnical generics will be added.

Due to the specifics in biotechnology, fulfilling the regulatory requirements in the manufacture and quality assurance of biotech products is a tremendous challenge, and industry as well as authorities are constantly challenged by new changes in regulation.

For these reasons this website will provide you with an overview about all courses and conferences in this area offered by the European Compliance Academy (ECA). Please use the navigation on the top to get to the single conferences and courses.